LeMaitre Vascular, Inc. $LMAT Stock: Geneva Capital Management LLC Decreases Stake

Geneva Capital Management LLC decreased its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 13.2% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 511,223 shares of the medical instruments supplier’s stock after selling 77,841 shares during the quarter. Geneva Capital Management LLC owned approximately 2.24% of LeMaitre Vascular worth $42,222,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. BlackRock Inc. bought a new position in LeMaitre Vascular in the 2nd quarter worth $314,075,000. Boston Trust Walden Corp bought a new stake in LeMaitre Vascular during the third quarter valued at about $28,546,000. Ranger Investment Management L.P. bought a new stake in LeMaitre Vascular during the second quarter valued at about $21,045,000. Rice Hall James & Associates LLC purchased a new position in shares of LeMaitre Vascular in the second quarter valued at about $18,223,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of LeMaitre Vascular in the second quarter valued at about $16,549,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on LMAT shares. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Wells Fargo & Company decreased their target price on LeMaitre Vascular from $94.00 to $86.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 5th. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a report on Thursday, November 5th. Finally, Weiss Ratings downgraded LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Three equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Hold” and an average target price of $108.25.

Read Our Latest Report on LeMaitre Vascular

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT opened at $78.29 on Monday. The company has a market cap of $1.79 billion, a P/E ratio of 28.47, a P/E/G ratio of 2.31 and a beta of 0.51. LeMaitre Vascular, Inc. has a 52-week low of $77.46 and a 52-week high of $118.01. The company has a debt-to-equity ratio of 0.39, a quick ratio of 12.54 and a current ratio of 14.60. The firm’s fifty day moving average is $81.31 and its two-hundred day moving average is $93.95.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $0.65 EPS for the quarter, missing the consensus estimate of $0.69 by ($0.04). The company had revenue of $67.97 million for the quarter, compared to the consensus estimate of $67.39 million. LeMaitre Vascular had a net margin of 23.51% and a return on equity of 15.33%. The firm’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same period last year, the company earned $0.75 EPS. As a group, analysts anticipate that LeMaitre Vascular, Inc. will post 2.83 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Thursday, November 19th will be given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date is Thursday, November 19th. LeMaitre Vascular’s payout ratio is currently 36.36%.

LeMaitre Vascular Profile

(Free Report)

LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.

See Also

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.